Global Diabetes Drugs and Devices Market Analysis: Oral, Injectable, Non-Injectable Drugs, Diagnostics and Forecast to 2020, New Findings by iHealthcareAnalyst, Inc.
Summary
The type of diabetes determines either blood sugar monitoring, insulin or oral medications as a treatment.Major players operating in the global diabetes drugs and devices market and included in this report are Abbott Laboratories, Inc., AstraZeneca plc, B Braun Melsungen AG, Bayer HealthCare AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, DexCom, Inc., Eli Lilly and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Medtronic, Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Sanofi, and Takeda Pharmaceutical Co. Ltd. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/diabetes-drugs-devices-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget.Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, February 14, 2017 --( PR.com )-- The global diabetes drugs and devices market is estimated to exceed USD 85 Billion in 2020, expanding at a CAGR of 4.4% from 2016 to 2020, due to rising diabetic population and associated diseases worldwide.Browse Diabetes Drugs and Devices Market by The Drug Type (Insulin Derivatives – Short-Acting, Intermediate-Acting, Long-Acting, Premixed, and Rapid-Acting Insulin; Oral Anti-Diabetes Drugs – Alpha-Glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides, SGLT-2 Inhibitors, Sulphonylureas, Thiazolidinediones; and Non-Insulin Injectable Anti-Diabetes Drugs – GLP-1 Analogs), Device Type (Diabetes Monitoring and Diagnostic Devices – Analog Glucose Meter, Continuous Glucose Monitoring Devices, Glucose Test Strips, Lancets and Lancing Devices; Insulin Delivery Devices – Insulin Injectors, Pens, Pumps, Syringes) 2016-2020 at https://www.ihealthcareanalyst.com/report/diabetes-drugs-devices-market/The elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination.Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Contact Information iHealthcareAnalyst, Inc. Ana Aitawa (314) 500-7508 https://www.ihealthcareanalyst.com/ Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc. Promote Your Business Press Release Pricing Email this page to a friend